BridgeBio Pharma (BBIO) Competitors

Beigene (NASDAQ:ONC) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.

Is ONC or BBIO more profitable?

Beigene has a net margin of -25.94% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Beigene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beigene	-25.94%	-25.12%	-14.95%
BridgeBio Pharma	-241.44%	N/A	-75.69%

Does the media prefer ONC or BBIO?

In the previous week, Beigene had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Beigene and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 1.30 beat Beigene's score of 0.54 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beigene	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend ONC or BBIO?

Beigene presently has a consensus target price of $316.67, indicating a potential upside of 30.44%. BridgeBio Pharma has a consensus target price of $52.64, indicating a potential upside of 51.12%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Beigene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beigene	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
BridgeBio Pharma	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Does the MarketBeat Community prefer ONC or BBIO?

BridgeBio Pharma received 170 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 72.02% of users gave BridgeBio Pharma an outperform vote while only 62.50% of users gave Beigene an outperform vote.

Company	Underperform	Outperform
Beigene	Outperform Votes 5 62.50%	Underperform Votes 3 37.50%
BridgeBio Pharma	Outperform Votes 175 72.02%	Underperform Votes 68 27.98%

Which has more risk & volatility, ONC or BBIO?

Beigene has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of ONC or BBIO?

48.5% of Beigene shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 7.4% of Beigene shares are held by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has stronger earnings and valuation, ONC or BBIO?

BridgeBio Pharma has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beigene	$3.81B	6.29	-$881.71M	-$6.14	-39.54
BridgeBio Pharma	$221.90M	29.85	-$535.76M	-$2.85	-12.22

Summary

BridgeBio Pharma beats Beigene on 13 of the 18 factors compared between the two stocks.